Immune Checkpoint Inhibition in Hodgkin Lymphoma
Abstract. Intricate systems of checkpoints such as the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis regulate adaptive immune responses to protect against tissue damage. However, diverse cancers can exploit these pathways to evade or suppress antitumor immunity, leadi...
Main Authors: | Ryan H. Moy, Anas Younes |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2018-02-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000020 |
Similar Items
-
Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
by: Valli De Re, et al.
Published: (2019-10-01) -
The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
by: Nicholas Meti, et al.
Published: (2018-06-01) -
Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma
by: Wenchao Li, et al.
Published: (2018-12-01) -
Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives
by: Diego De Goycoechea, et al.
Published: (2019-01-01) -
Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors
by: Maansi Joshi, et al.
Published: (2020-01-01)